Merck notches fourth lung cancer approval in Europe for flagship Keytruda

Merck notches fourth lung cancer approval in Europe for flagship Keytruda

Source: 
Endpoints
snippet: 

Merck’s keystone immunotherapy Keytruda has won yet another lung cancer approval in Europe, this time as the first line of defense for patients with metastatic squamous non-small cell lung cancer (NSCLC), on the basis of trial data that showed the drug — as part of a chemotherapy combo — cut the risk of death by 36% versus chemotherapy alone.